UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 ________________________________________ ...

Schrödinger, Inc. (NASDAQ:SDGR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations and Corporate Affairs Ramy Farid - Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President of R&D, Therapeutics Conference Call Participants Do Kim - Piper Sandler David Lebowitz - Citi Gary Nachman - BMO Capital Markets Wolf Chanoff - Bank of America Operator Thank you for standing by. Welcome to Schröd ...

Enhanced Platform Capabilities • Initiated SGR-1505 Phase 1 trial Second Quarter 2022 Supplemental Slides February 28, 2023 Transforming Discovery of Therapeutics and Materials This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-K _______________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39206 _______________________________________ Schrod ...

Schrödinger, Inc. (NASDAQ:SDGR) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR and Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President, R&D, Therapeutics Conference Call Participants Do Kim - Piper Sandler David Lebowitz - Citi Gary Nachman - BMO Capital Markets Vikram Purohit - Morgan Stanley Gaurav Goparaju - Berenberg Capital Markets Operator Everyone, thank you for standing by. Welcome to Schrödinger Conference Call t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 _____________________________________ ...

Schrodinger, Inc. (NASDAQ:SDGR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Communications Ramy Farid - CEO, President & Director Jenny Herman - SVP, Finance & Corporate Controller Karen Akinsanya - President, Research & Development Therapeutics Conference Call Participants Michael Ryskin - Bank of America Merrill Lynch Gary Nachman - BMO Capital Markets Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrö ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 Schrodinger, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4284541 (State or other jurisdiction of ...

Transforming Discovery of Therapeutics and Materials May 4, 2022 First Quarter 2022 Supplemental Slides Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding the potential advantages of our physics-b ...

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Jaren Madden – Senior Vice President of Investor Relations and Corporate Affairs Ramy Farid – Chief Executive Officer Jenny Herman – Senior Vice President of Finance and Corporate Controller Karen Akinsanya – President of R&D, Therapeutics Conference Call Participants Vikram Purohit – Morgan Stanley David Lebowitz – Citi Andrew Tsai – Jefferies Gaurav Goparaju – Berenberg Capital Operator Welcome to ...